companiesCompany
Nuvalent
Designer of cleaner kinase inhibitors; zidesamtinib (ROS1) approved July 2026, neladalkib (ALK) next.
Zidesamtinib (Jideytro), neladalkib (ALK, ALKOVE-1), HER2-selective programme.
ApprovedSmall-molecule kinase inhibitor (ROS1)
Zidesamtinib · Jideytro
A ROS1 inhibitor approved in July 2026 that works after other ROS1 drugs fail and avoids their brain side effects.
Phase 3Small-molecule kinase inhibitor (ALK)
Neladalkib
A fourth-generation ALK pill that works after lorlatinib and avoids the TRK-related brain side effects; under FDA priority review with a decision due 27 November 2026.
Pages like this
not linked directly; found by shared links- TrialALKOVE-1
Shares Neladalkib, Non-small-cell lung cancer.
- ProductRepotrectinib
Shares Zidesamtinib, Non-small-cell lung cancer.
- ProductAlectinib
Shares Neladalkib, Non-small-cell lung cancer.
- TargetROS1
Shares Zidesamtinib, Non-small-cell lung cancer.
- ProductLorlatinib
Shares Neladalkib, Non-small-cell lung cancer.